Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of acalabrutinib with rituximab and lenalidomide in relapsed/refractory B-cell non-Hodgkin lymphoma
KCT0003724Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib, rituximab, lenalidomide in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Acerta Pharma. Started Jul 2019; status: completed.
02
Drugs
acalabrutinibrituximablenalidomide
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on KCT0003724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003724.